Their mechanism gives them two major downstream effects of interest: improved glycemic control and weight reduction (due to appetite reduction + slower gastric emptying) plus other possible metabolic benefits
With most regions of the world running fewer than 2000 clinical trials a year in 2001, the number has increased dramatically in the present day (1)
Clinical trial outcomes represent population averages under controlled conditions
Notable among these are: Gastroparesis: A less common but serious condition where the stomach empties slowly, leading to nausea, vomiting, and bloating
These medicines help by: Some medicines, such as Mounjaro (tirzepatide) , also activate GIP (glucose-dependent insulinotropic polypeptide) receptors, providing additional metabolic benefits
n organism, acioneaz ca un purttor care transport grsimea (acizii grai) ctre celule, unde este ars pentru energie